There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AnaptysBio Inc (ANAB), Trevena Inc (TRVN) and Sutro Biopharma Inc (STRO) with bullish sentiments.
AnaptysBio Inc (ANAB)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on AnaptysBio Inc today and set a price target of $126. The company’s shares closed on Friday at $59.24, close to its 52-week low of $54.26.
Fein observed:
“We also think that there is more than one way to differentiate other than efficacy (safety or dosing regimen matters too). Even in the case of etokimab showing comparable efficacy and safety as dupilumab, we still think that a fraction of patients who do not respond to dupilumab can potentially benefit from etokimab.”
According to TipRanks.com, Fein is a 3-star analyst with an average return of 0.7% and a 43.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Proteostasis Therapeutics Inc, and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on AnaptysBio Inc is a Moderate Buy with an average price target of $113, which is a 90.7% upside from current levels. In a report issued on June 21, Jefferies also reiterated a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Trevena Inc (TRVN)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Trevena Inc today and set a price target of $3.50. The company’s shares closed on Friday at $1.01.
Tsao wrote:
“Our $3.50 price target for Trevena is based on our sum-of- the-parts NPV valuation of each of the company’s pipeline assets. Our DCF model utilizes a discount rate of 11.5% based on the company’s WACC (Beta of 1.5, equity risk premium of 6.7%).”
According to TipRanks.com, Tsao is a 3-star analyst with an average return of 1.6% and a 49.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals Inc, Minerva Neurosciences, and Revance Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Trevena Inc with a $3.50 average price target.
Sutro Biopharma Inc (STRO)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Sutro Biopharma Inc today and set a price target of $18. The company’s shares closed on Friday at $11.87.
Chattopadhyay noted:
“Valuation and risks to our investment thesis. Our 12-month, $18 price target on shares of Sutro is derived from a 13-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.60, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.3%, and tax rate of 15% beginning in FY 2029. Until clarity on Sutro’s collaboration with not rated) crystallizes, our $18 price target remains leveraged on the outcome of STRO-002’s safety and efficacy outcome, which represents approximately 67% of our rNPV of $12 per share.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.5% and a 45.4% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sutro Biopharma Inc with a $20 average price target, a 68.5% upside from current levels. In a report issued on June 16, Cowen & Co. also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
